turoctocog alfa pegol (N8-GP)

DRUG2 trials

Sponsors

Novo Nordisk A/S

Conditions

Haemophilia A

Phase 3

Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)

CompletedNCT05082116

Novo Nordisk A/SHaemophilia A

Start: 2021-09-27End: 2022-12-28Updated: 2026-01-06

Unknown Phase

A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®

Enrolling by invitationNCT04574076

Novo Nordisk A/SHaemophilia A

Start: 2020-10-23End: 2027-06-03Target: 60Updated: 2025-12-22

Related Papers

The efficacy, safety, and pharmacokinetics of N8-GP in previously treated Chinese patients with haemophilia A: results from the phase 3b pathfinder10 study.

2025-09-03